Group 1 - Pfizer's price increases for most drugs are below 10%, but the COVID-19 vaccine price has risen by approximately 15%, with some commonly used hospital drugs seeing price increases of over four times [1][4] - In 2026, over 350 drugs in the U.S. are expected to see price increases, including COVID-19 vaccines, respiratory syncytial virus vaccines, shingles vaccines, and some major cancer treatment drugs [2][4] - The number of drugs experiencing price increases in 2026 has increased compared to the previous year, while the magnitude of the increases remains largely consistent with last year [4] Group 2 - Pfizer has announced the largest price increases among pharmaceutical companies, affecting around 80 different drugs, including cancer medications, migraine treatments, COVID-19 drugs, and commonly used hospital pain medications like morphine and hydromorphone [4] - GSK plans to raise prices on about 20 drugs and vaccines by 2% to 8.9%, stating that the increases are necessary to support scientific innovation and maintain reasonable drug prices [4] - Pfizer stated that the average price adjustment for innovative drugs and vaccines in 2026 is set below the overall inflation rate, emphasizing that small price increases are necessary to support ongoing investments in new drug development and to address rising costs [4]

Core Insights - Deals between pharmaceutical companies and the U.S. government aimed at reducing drug prices are expected to increase the cost of new drugs in Switzerland, according to the CEO of Roche [1] Group 1: Impact on Drug Pricing - The agreements in the U.S. to lower medicine prices may lead to higher costs for new pharmaceuticals in Switzerland [1]

Core Viewpoint - Eli Lilly (LLY.US) has suspended the shipment of its weight loss drug Mounjaro in the UK, with a new price increase set to take effect next month [1] Group 1: Company Actions - The company has reserved allocations for pharmacies and suppliers to manage supply and ensure continuous access for patients [1] - Legal measures have been taken to prevent suppliers from hoarding the drug, with orders expected to resume on September 1 [1] Group 2: Pricing Strategy - Eli Lilly plans to increase the price of Mounjaro in the UK by up to 170%, raising the monthly supply price from £122 to £330 for the highest dosage [1] - Despite the significant price hike, the company has committed not to raise the supply price to the National Health Service (NHS) to ensure ongoing availability of the drug [1]

Group 1 - The company Eli Lilly has suspended the shipment of its weight loss drug Mounjaro in the UK, with a new price increase set to take effect next month [1] - To manage supply and ensure patients can continuously access the medication, the company has allocated quotas for pharmacies and suppliers that order the drug [1] - Eli Lilly plans to raise the price of Mounjaro in the UK by up to 170% in September, with the highest dosage monthly supply price increasing from £122 to £330 (approximately $164.81 to $445.80) [1] Group 2 - The company has taken legal measures to prevent suppliers from improperly stockpiling the medication [1] - Orders are set to resume on September 1 [1] - The price increase comes amid pressure from the White House for pharmaceutical companies to raise drug prices in Europe to create room for price reductions in the US [1]